A Case of Recurrent Esophagogastric Junction Cancer Responding to Trastuzumab

: We report a case of recurrent esophagogastric junction cancer successfully treated with chemotherapy including trastuzumab. A 66-year-old man reporting black stool was examined, and through upper gastrointestinal endoscopy was found to have a tumor at the esophagogastric junction. Video-assisted thoracoscopic surgery of the esophagus with 3-field lymph node dissection was performed. The final diagnosis was adenocarcinoma(tub1-pap-muc), pT3N3M0, pStage III C. The tumor was at the squamo-columnar junction and classified as Siewert type II . Following surgery, 6 months of adjuvant therapy with S-1 was administered. Computed tomography(CT)confirmed metastases in the lung, liver, and recurrence in the reconstructed stomach. In spite of chemoradiotherapy(FP plus RT)and weekly PTX, these metastases had grown. Pathological examinationshowed overexpressionof humanepidermal growth factor receptor 2(HER2), and treatment with CPT- 11 plus trastuzumab was initiated at postoperative 15 months. A partial response was achieved 3 months later. The lesions in the lung, liver, and reconstructed stomach were controlled with this therapy, but he died from meningeal seeding at postoperative 20 months. These findings suggest that inclusion of trastuzumab in chemotherapy regimens is effective for recurrent HER2-positive esophagogastric junction cancers.